Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NIH Puts New Clinical Trial Guidelines Into Effect

Researchers requesting funding for clinical trials must determine if their research meets new criteria set by new NIH guidelines. The new guidelines breaks from the traditional understanding to also  include both basic biomedical research and basic social and behavioral research. The switch has caused somewhat of a controversy, with some researchers claiming that the guidelines…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Researchers requesting funding for clinical trials must determine if their research meets new criteria set by new NIH guidelines. The new guidelines breaks from the traditional understanding to also include both basic biomedical research and basic social and behavioral research.

The switch has caused somewhat of a controversy, with some researchers claiming that the guidelines are too broad, and the new policies will increase researcher burdens. In September, more than 3500 scientists signed an open letter requesting NIH to delay the policy. Researchers conducting trials are now required to register and report results on ClinicalTrials.gov, but, if researchers impacted by the change do not select a funding opportunity that supports clinical trials when they apply to NIH, their grant is subjected to be rejected without a review.

Though some clarification from NIH in recent months has quelled many of the concerns expressed, some researchers have lingering doubts. “There’s still a problem, but the problem is less dire than the original set of concerns that we had,” says cognitive psychologist Jeremy Wolfe of the Harvard University.[1]

The guidelines go into effect on January 25th.

[1]

http://www.sciencemag.org/news/2018/01/nih-s-new-clinical-trial-policy-kicks-despite-concerns-basic-behavioral-researchers

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitor messaging suggests compliance testing and AI-ready compute are becoming early decisions, not afterthoughts. Medical Economics described 2026 as a period shaped by rapid technological change, regulatory scrutiny and ongoing economic uncertainty. Medical Design & Outsourcing’s MD&M West 2026 preview points to exhibitors highlighting test equipment, contract manufacturing and other launch support services.

  • 01If a device roadmap includes AI features, the critical path shifts toward data and software evidence that regulators can audit, which means earlier lock-in of compute platforms and test plans, pulling verification and validation into supplier selection.
  • 02MD&M West exhibitor messaging suggests verification and validation capacity is becoming a procurement problem, with rentals and lab-ready gear positioned as a way to avoid booking delays and re-tests, according to Medical Design & Outsourcing.
  • 03With imaging and other new procedural and device concepts moving fast, manufacturing leaders should expect more frequent line-change decisions and component qualification work, as GE HealthCare's photon-counting CT CE mark reported by MedTech Dive and MDDI's New Technologies coverage illustrate.

Sep 3, 2026

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz brings 23+ years of experience as chief medical physicist at Texas Oncology and personal insight as a breast cancer survivor, enabling her to guide patient support groups and advocate for accessible cancer care. She emphasizes AI's potential in auto-contouring and treatment planning while stressing the need for proper training, validation, and transparency before implementation.

  • 01Over 23 years at Texas Oncology integrating personal cancer survivor experience with clinical expertise to improve patient empathy and support group leadership
  • 02AI in oncology requires human oversight, validation, and transparency; auto-contouring and auto-planning must be combined with staff training and rigorous protocol testing before deployment
  • 03Texas Oncology prioritizes offering state-of-the-art cancer treatments closer to home, including for rural patients, to reduce travel and ensure consistent, personalized care

Sep 3, 2026

ADA endorsement puts Weave on the shortlist for dental front-office tech

ADA endorsement puts Weave on the shortlist for dental front-office tech

Weave was named the exclusive patient engagement platform endorsed for American Dental Association members in March 2026. It lands as practices add more front-office systems. Weave’s Practice Analytics, launched in 2023, adds real-time metrics tied to Dentrix, Open Dental, and Eaglesoft.

  • 01Endorsements are becoming a procurement accelerant in dental tech: the ADA Member Advantage designation can move Weave into “default vendor” conversations when practices refresh phone, texting, reminders, and payments.
  • 02Analytics is moving from retrospective reporting to daily work queues: Weave’s Practice Analytics is positioned around unscheduled treatment plans, cancellations, and time-between-treatments, metrics that can be assigned to staff, not just reviewed by owners (according to Dental Products Report).
  • 03This matters most for groups standardizing across multiple sites: Business Wire frames Weave Enterprise as built to centralize operations across dozens or hundreds of locations, turning “patient communication” into a rollout and governance problem, not a single-office tool choice.

Sep 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512